Company profile
Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Nomlabofusp | phase2 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05579691 | phase2 | completed | 2022-09-21 | 2023-12-04 | Larimar Therapeutics, Inc. | A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia |
| NCT06681766 | phase1 | terminated | 2024-12-06 | 2025-04-27 | Larimar Therapeutics, Inc. | A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia |
| NCT07778836 | phase3 | recruiting | 2026-08-05 | 2029-07-01 | Larimar Therapeutics, Inc. | A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia |
| NCT06447025 | phase2 | recruiting | 2024-01-25 | 2027-01-01 | Larimar Therapeutics, Inc. | An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia |
| NCT04519567 | phase1 | completed | 2020-07-31 | 2021-03-16 | Larimar Therapeutics, Inc. | Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia |
FDA applications (0)
No records yet.